关键信息
-
基因名
MTMR7
- 应用
-
别名
MTMR7; Myotubularin-related protein 7; Inositol 1,3-bisphosphate phosphatase; EC 3.1.3.-; Phosphatidylinositol-3-phosphate phosphatase; EC 3.1.3.64
-
种属
Human
-
表达系统
E. coli
-
标签
N- His-SUMO
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q9Y216
-
表达区间
1-660aa
-
分子量
91.8 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
质检流程
相关产品
背景信息
MTMR7 (Myotubularin-related protein 7) is a member of the myotubularin family, which is characterized by its lipid phosphatase activity involved in the regulation of phosphoinositides, critical for various cellular processes, including membrane trafficking and cytoskeletal dynamics. Mutations in the MTMR7 gene are associated with human disorders, particularly Charcot-Marie-Tooth disease type 4B (CMT4B), a hereditary neuropathy that leads to progressive muscle weakness and atrophy. The study of MTMR7 recombinant protein has gained significant interest as understanding its enzymatic properties and interactions can provide insights into the pathogenesis of CMT4B and other related conditions. Research has focused on characterizing the protein's structure, function, and the impact of specific mutations on its activity, which are crucial for developing therapeutic interventions. Moreover, examining MTMR7's role in phosphoinositide metabolism can illuminate its broader involvement in cellular signaling pathways and its potential implications in neurodegenerative diseases. By producing recombinant MTMR7, scientists aim to facilitate structure-function studies and high-throughput screening for small molecules that could modulate its activity, ultimately leading to novel therapeutic strategies for patients affected by MTMR7-related disorders. As our understanding of MTMR7 evolves, it poses significant potential for advancing treatments for inherited neuropathies and enhancing our knowledge of cellular mechanisms underlying these complex diseases.
